NE3107 was reported to have turned back t... - Cure Parkinson's
NE3107 was reported to have turned back the biological clock of Alzheimer’s patients – this may be world news.
BioVie Announces Positive Results for NE3107 in Parkinson's and Alzheimer's Phase 2 Trials
NE3107-treated patients experienced greater motor control in Parkinson’s trial
Patients treated with the combination of NE3107 and levodopa saw improvements in their UPDRS Part 3 (motor) score that is 3+ points superior to patients treated with levodopa alone. This level of superiority is considered to be clinically meaningful by Parkinson’s experts.
Patients under 70 years of age treated with NE3107/levodopa experienced roughly 6 points superiority compared to those treated with levodopa alone, suggesting that younger patients with less advanced disease progression may experience greater impact from treatment with NE3107.
88.9% of patients <70 years old treated with NE3107 and levodopa experienced greater than 30% part 3 score improvements from baseline at the 2-hour mark compared to 63.6% of patients treated with levodopa alone.
The study met both of its objectives.
NE3107-treated patients experienced improved cognition and biomarker levels in Alzheimer’s trial
Patients treated with NE3107 experienced enhanced cognition as measured by multiple assessment tools, including a 2.1 points improvement on the modified ADAS-Cog12 scale (p=0.0173) among MCI and mild Alzheimer’s Disease (AD) patients
NE3107 reduces CSF phospho-tau levels by -1.66 pg/mL (p=0.0343) and the ratio of p-tau to Aß42 by -0.0024 (p=0.0401)
18 of 22 patients with abnormal baseline scans showed improvement in one or more brain regions as seen from advanced functional MRI studies
No drug-related adverse events were observed
tmcnet.com//usubmit/2022/12...
Another one. There's some good stuff out there
Good stuff.
This sounds pretty good to me but I'm not real good at reading some of the details on things like this. How long do you think it would take to get through all the phases they need to go through? A year, 3 years, longer?? 🥊
So it sounds like it reduces inflammation so is the benefit that it can do this in the brain while maybe some other things designed to reduce inflammation cannot?
BioVie’s investigational oral therapy NE3107, taken in combination with standard levodopa, eases motor symptoms more substantially than levodopa alone in people with Parkinson’s disease, according to top-line results of a Phase 2 clinical trial.
NE3107 shows promise, and if the current findings are confirmed, it may represent one of the most significant advances in Parkinson’s treatment in decades
End-of-study results showed that the reduction in UPDRS motor scores at two and three hours post-treatment was three points greater in patients given NE3107 plus levodopa than in those given levodopa alone. That “is a very meaningful clinical benefit,”
“My review of the BioVie study of NE3107 in Parkinson’s Disease suggests that there is a probable signal of clinical efficacy in the treatment of motor symptoms. This signal should be pursued in a larger, focused, confirmatory study,” said Douglas Felter, MD, PhD. A former pharma executive experienced in Parkinson’s drug development and now working as a consultant, Felter was not directly involved in the trial.
NE3107 is also being developed as a potential therapy for Alzheimer’s, the most common cause of dementia. In its release, BioVie also reported findings in a small, open-label Phase 2 trial that indicated the therapy led to improvements in cognitive tests and reductions in disease biomarkers among Alzheimer’s patients.
Maybe I've got a virus. When I clicked on this thread this came up:
Navigate the Stock Market with Seeking Alpha
So I'm deleting all of it.
